LUNGCARD

Point-of-care blood device for fast and reliable prediction of drug response in non- small-cell lung carcinoma patients from blood samples

Coordinatore	"STAB VIDA, INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA."    more  Organization address address: RUA DOS INVENTORES SN EDIFICIO MADAN SETUBAL CONCELHO ALMADA FREGUESIA CAPARICA E TRAFARIA city: OEIRAS postcode: 2825 182 contact info Titolo: Dr. Nome: Orfeu Cognome: Flores Email: send email Telefono: 351210000000
Nazionalità Coordinatore	Portugal [PT]
Sito del progetto	http://www.lungcard.eu/
Totale costo	1˙479˙574 €
EC contributo	1˙056˙000 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2012
Funding Scheme	BSG-SME
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-02-07   -   2015-02-06

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	"STAB VIDA, INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA."  Organization address address: RUA DOS INVENTORES SN EDIFICIO MADAN SETUBAL CONCELHO ALMADA FREGUESIA CAPARICA E TRAFARIA city: OEIRAS postcode: 2825 182 contact info Titolo: Dr. Nome: Orfeu Cognome: Flores Email: send email Telefono: 351210000000	PT (OEIRAS)	coordinator	301˙782.00
2	microLIQUID sl  Organization address address: Av. Uribarri 19-1 city: Arrasate-Mondragon postcode: 20500 contact info Titolo: Mr. Nome: Borja Cognome: Barredo Email: send email Telefono: 34943712072	ES (Arrasate-Mondragon)	participant	405˙355.60
3	MOLTECH SRL  Organization address address: VIA ROMA 72 city: FILIGNANO IS postcode: 86074 contact info Titolo: Mr. Nome: Giovanni Ugo Cognome: Altieri Email: send email Telefono: 390866000000	IT (FILIGNANO IS)	participant	339˙213.40
4	HULL AND EAST YORKSHIRE HOSPITALS NATIONAL HEALTH SERVICE TRUST  Organization address address: ANLABY ROAD HULL ROYAL INFIRMARY city: HULL postcode: HU3 2JZ contact info Titolo: Prof. Nome: Michael Cognome: Lind Email: send email Telefono: 441482000000 Fax: 441482000000	UK (HULL)	participant	9˙649.00
5	FUNDACAO DA FACULDADE DE CIENCIAS E TECNOLOGIA DA UNIVERSIDADE NOVA DE LISBOA.  Organization address address: "Campus de Caparica, Quinta da Torre S/N" city: CAPARICA postcode: 2829516 contact info Titolo: Ms. Nome: Ana Luísa Cognome: Baião Email: send email Telefono: 351213000000 Fax: 351213000000	PT (CAPARICA)	participant	0.00
6	INSTITUTE OF PHOTONIC TECHNOLOGY E.V.  Organization address address: Albert Einstein strasse 9 city: JENA postcode: 7745 contact info Titolo: Dr. Nome: Gabriele Cognome: Hamm Email: send email Telefono: 493641000000 Fax: 493641000000	DE (JENA)	participant	0.00
7	UNIVERSITY OF HULL  Organization address address: COTTINGHAM ROAD city: HULL postcode: HU6 7RX contact info Titolo: Prof. Nome: Steven Cognome: Haswell Email: send email Telefono: 441482000000	UK (HULL)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, however most of non-small cell lung cancer tumours are not sensitive to this treatment. As an alternative to chemoterapy, target therapy with gefitinib (epidermal growth factor receptor-tyrosine kinase inhibitor) has been used in clinical practice in patients with tumours harbouring mutations in EGFR gene, improving their treatment effectiveness. For that reason EGFR mutations analysis should be perform to support the treatment decision for a patient with NSCLC. Despite all the foreseen benefits of EGFR genotyping, the current PCR-based methods used have been shown some associated bottlenecks: i) use of complex samples (tumour biopsy embedded in Formalin Fixed Paraffin, FFPE), ii) require a better understanding from the clinical geneticist to accurately interpret the information provided and to setup the best line of therapy and treatment and iii) the assays are quite expensive and time-consuming. New age diagnostic tools, such as microfluidic platforms and nanodiagnostics are emerging technologies for DNA analysis requiring lower sample volumes and providing comparable sensitivity and specificity at lower costs. Nonetheless, sample preparation and detection of the result of a chemical analysis on-chip are still weak points in many lab-on-a-chip devices. The current proposal, aiming the integration of “all laboratory-based process steps” in one single step, is both challenging and feasible: development of a microfluidic chip that combines blood sample processing (DNA extraction/purification, multiplex amplification) and detection of EGFR mutations in tumour DNA by means of gold and silver-nanoparticles (Ag and Au-nanoprobes). Furthermore a microfluidic chip analyser with an integrated user-friendly software to report genotyping results will be developed.'

Introduzione (Teaser)

New-generation diagnostic tools utilise microfluidic chips and nanotechnology to analyse DNA from blood samples. An innovative blood assay harnessing these technologies is being developed for genotyping lung cancer patients.